XML 21 R29.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $) | 0 Months Ended |  |  | 3 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 08, 2014 Program | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 California Institute for Regenerative Medicine [Member] | Mar. 31, 2013 California Institute for Regenerative Medicine [Member] | Mar. 31, 2014 Beta-thalassemia [Member] California Institute for Regenerative Medicine [Member] | Mar. 31, 2014 License agreement terms [Member] California Institute for Regenerative Medicine [Member] | Mar. 31, 2013 License agreement terms [Member] California Institute for Regenerative Medicine [Member] | Jun. 30, 2012 Shire AG [Member] Targets | Jan. 31, 2012 Shire AG [Member] Targets | Mar. 31, 2014 Shire AG [Member] Product | Mar. 31, 2013 Shire AG [Member] | Jan. 08, 2014 Biogen [Member] | Mar. 31, 2014 Biogen [Member] | Jan. 08, 2014 Biogen [Member] Beta-thalassemia [Member] | Jan. 08, 2014 Biogen [Member] Sickle cell disease [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of research programs | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  |  |  |  |  |  | $ 13,000,000 |  |  | $ 20,000,000 |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  |  |  | 293,800,000 |  | 7,500,000 | 7,500,000
Research program to develop laboratory research reagents |  |  |  |  |  |  |  |  |  |  | 6 years |  |  | 40 months |  |
Deferred revenue |  | 8,548,000 | 2,282,000 |  |  |  |  |  |  |  | 8,400,000 |  |  | 19,300,000 |  |
Aggregate number of gene targets |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |  |
Number of initial gene targets |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |
Number of gene targets |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |
Number of additional gene targets |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
Potential amount to be funded for certain Shire milestones |  |  |  |  |  |  |  |  |  |  | 213,500,000 |  |  |  |  |
IND or CTA submission amount |  |  |  |  |  |  |  |  |  |  | 8,500,000 |  |  |  |  |
Number of products approved |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Royalty revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Collaboration agreement related costs and expenses |  |  |  | 300,000 | 400,000 | 1,300,000 |  |  |  |  | 4,800,000 | 3,100,000 |  |  |  |
Revenues under agreement |  |  |  |  |  | $ 400,000 | $ 0 | $ 400,000 |  |  |  |  |  |  |  |

X
- Definition Aggregate additional revenue recognition milestone method revenue to be recognized. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate number of gene targets. + References No definition available. + Details
Name: | sgmo_AggregateNumberOfGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement related costs and expenses. + References No definition available. + Details
Name: | sgmo_CollaborationAgreementRelatedCostsAndExpenses
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Payments Payable + References No definition available. + Details
Name: | sgmo_MilestonePaymentsPayable
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of additional gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfAdditionalGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of initial gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfInitialGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Research Program + References No definition available. + Details
Name: | sgmo_NumberOfResearchProgram
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research grant revenue. + References No definition available. + Details
Name: | sgmo_ResearchGrantRevenue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration